Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
Phase 2 Study of HKI-272 In Subjects With Advanced Breast Cancer
Sponsor: Puma Biotechnology, Inc.
A PHASE2 clinical study on Breast Neoplasms and Neoplasms, this trial is completed. The trial is conducted by Puma Biotechnology, Inc. and has accumulated 11 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Aug 2018 — Sep 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Aug 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Puma Biotechnology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .